ATAI

Several events have impacted ATAI's stock price in the past six months. The merger with Beckley Psytech Limited was expected to close in the second half of 2025. Positive topline data from the Phase 2b clinical trial of BPL-003 in treatment-resistant depression were reported, and the Phase 3 program is on track for initiation in Q2 2026. Positive topline results from an exploratory Phase 2a trial of EMP-01 in social anxiety disorder were announced in February 2026. In February 2025, the company completed an equity offering with net proceeds of $59.2 million, extending its cash runway into 2027, and in August 2025, the company reported Q2 2025 financial results, with revenues tripling year-over-year. Multiple analyst firms have reiterated or raised their price targets and maintained positive ratings on ATAI. AtaiBeckley is expected to report Q1 2026 results around May 11, 2026.